$ cat ./records/gates-foundation-grants-over-1-million-to-ceres-nanosciences-for--2017.txt
Gates Foundation Grants Over $1 Million to Ceres Nanosciences for Lyme Disease Diagnostic Technology
[RECORD.TXT] · cat --full
The Bill & Melinda Gates Foundation awarded over $1 million to Ceres Nanosciences — a Virginia-based diagnostics company — to develop its Nanotrap particle-based Lyme disease diagnostic. The Nanotrap platform concentrates biomarkers from urine samples, offering the potential for a more sensitive and specific antigen test than existing two-tier serology tests, which miss a significant proportion of early infections. Current standard Lyme diagnostics are unreliable in the first weeks after tick bite. The technology was also being evaluated for tuberculosis and Ebola diagnostics.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Foundation Supports Acaricide Resistance Monitoring Network Across Kenya and Tanzania
Next →
Gates Foundation Co-founds CEPI to Cut Vaccine Development Time to Under One Year
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.